分子肿瘤委员会对患者诊疗的临床影响与结构特征:系统综述与荟萃分析
该系统综述与荟萃分析检索截至2025年7月的多个数据库,纳入78项研究共9195例患者,评估分子肿瘤委员会(MTB)推荐治疗的临床影响。MTB指导治疗与疾病进展风险降低(HR 0.73)和客观缓解率提高(RR 1.75)相关,总生存获益有限(HR 0.87,P=0.069)。
要点
- MTB指导治疗可显著降低疾病进展风险并提高客观缓解率和疾病控制率。
- 总生存获益未达统计学显著性,需谨慎解读。
- 多数非随机研究存在严重偏倚风险,证据质量有限。
核心结论
- 来自随机对照试验的稳健证据支持MTB的临床获益,但总生存获益有限。
- 观察性研究的方法学异质性和局限性要求谨慎解读结果。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus和CENTRAL至2025年7月。
- 纳入任何设计的研究,包括单臂研究和有对照的研究,报告MTB指导治疗的临床影响。
- 共纳入78项研究,9195例患者,其中4569例按MTB推荐接受治疗。
- 采用随机效应模型,基于逆方差法进行荟萃分析。
- 使用RoB 2.0评估随机对照试验偏倚风险,ROBINS-I评估非随机研究。
主要发现
- MTB指导治疗与死亡风险降低相关(HR 0.87;95%CI [0.76, 1.01];P=0.069;随机对照试验中I2=0.0%;回顾性研究中为0.62)。
- MTB指导治疗与疾病进展风险降低相关(HR 0.73;95%CI [0.64, 0.84];P<0.001;随机对照试验中I2=0.0%;回顾性研究中为0.63)。
- MTB指导治疗与客观缓解率提高相关(RR 1.75;95%CI [1.24, 2.47];P=0.001;随机对照试验中I2=0.0%;回顾性研究中为3.32)。
- MTB指导治疗与疾病控制率提高相关(RR 1.20;95%CI [1.03, 1.40];P=0.018;随机对照试验中I2=19.9%;回顾性研究中为1.65)。
- 33%至43%的患者达到PFS比值≥1.3。
关键数值与推荐
- 随机对照试验偏倚风险总体低,仅一项研究被评为存在一些担忧。
- 多数非随机研究(n=54)的总体偏倚风险被评为严重。
临床怎么用
- MTB指导治疗可改善疾病进展和缓解率相关结局,支持其在肿瘤临床决策中的应用。
- 总生存获益尚不明确,临床决策需结合其他证据。
- 未来需要高质量随机对照试验和标准化报告来确认发现并指导MTB整合。
局限性
- 存在显著异质性。
- 非随机研究占多数且存在偏倚风险。
- 数据报告存在局限性,限制因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular Tumor Boards (MTBs) bring together multidisciplinary experts to translate genomic data into clinical decisions in oncology, however, their overall clinical impact remains unclear. The aim of this systematic review is to assess the clinical impact of MTB-recommended therapies on patients with cancer outcomes. METHODS AND FINDINGS: In this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and CENTRAL up to July 2025. We included studies of any design, both single-arm studies and studies with a comparator group, that reported the clinical impact of MTBs in patients who received MTB-guided therapy. Meta-analyses were performed separately by study design, using hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), relative risks (RRs) for objective response rate (ORR) and disease control rate (DCR), and pooled proportions for PFS ratio ≥1.3. All meta-analyses were conducted using random-effects models based on the inverse variance method. We evaluated the risk of bias using the RoB 2.0 for RCTs and ROBINS-I for non-randomized studies. From 6,846 records, 78 studies (9,195 patients; 4,569 treated per MTB recommendations) were included. MTB-guided therapies were associated with reduced risk of death (HR 0.87; 95% CI [0.76, 1.01]; p = 0.069; I2 = 0.0% in RCTs; 0.62 in retrospective studies) and disease progression (HR 0.73; 95% CI [0.64, 0.84]; p < 0.001; I2 = 0.0% in RCTs; 0.63 in retrospective studies), as well as improved ORR (RR 1.75; 95% CI [1.24, 2.47]; p = 0.001; I2 = 0.0% in RCTs; 3.32 in retrospective studies) and DCR (RR 1.20; 95% CI [1.03, 1.40]; p = 0.018; I2 = 19.9% in RCTs; 1.65 in retrospective studies). Between 33% and 43% of patients achieved a PFS ratio ≥1.3. While the risk of bias for RCTs was low, except for one study that was rated as having some concerns, the overall risk of bias for non-randomized studies was rated as "serious" in most of the studies (n = 54). Limitations include substantial heterogeneity, predominance of non-randomized studies with risk of bias, and limitations in data reporting, which restrict causal inference. CONCLUSIONS: This meta-analysis provides robust evidence from RCTs supporting the clinical benefit of MTBs, although limited for OS. Methodological heterogeneity and study limitations from observational studies warrant cautious interpretation. Future high-quality RCTs and standardized reporting are needed to confirm these findings and guide the integration of MTBs into routine clinical practice and health system strategies.
引用
- Russo L, Giacobini E, Lentini N, et al. Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis. PLoS Med. 2026. PMID: 42263112. doi:10.1371/journal.pmed.1005125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。